| WARF: P95123US |  |
| Method of Treating Proliferative Skin Disorders with 19-Nor-Vitamin D Compounds |
| INVENTORS | • | Hector DeLuca, Heinrich Schnoes, Kato Perlman, Rafal Sicinski, Jean Prahl |
OVERVIEW
This invention provides a novel class of Vitamin D-related compounds, namely the 1 alpha-hydroxy-19-nor-vitamin D analogs, as well as a general method for their chemical synthesis. The compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells, including malignant cells, and in inducing their differentiation, and thus represent novel therapeutic agents for the treatment of malignant and other diseases characterized by the proliferative growth of undifferentiated cells. Formulation for therapeutic use and treatment methods are also provided. The 19-nor analogs useful herein are of the general formula ##FORMULA## where X1 and X2 each hydrogen, acyl, alkylisilyl or alkoxyalkyl, and where R is any of the typical side chain known for Vitamin D type compounds.
ADDITIONAL INFORMATION
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Vitamin D
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
